Legal psychedelic therapy in Canada — what's actually available in 2026

If you're in Canada and wondering whether psychedelic-assisted therapy is something you can access legally, the answer is: it depends on the substance, your situation, and what specifically you're looking for. The landscape has been changing, and what was true two years ago may not be accurate now.

Here's a clear summary of what's actually available in Canada as of 2026 — including what requires a clinical setting versus what can be done in a therapy context without being present during an experience.

Key takeaways

• Ketamine is the most accessible legal option — clinics operate across Canada offering ketamine infusions and ketamine-assisted therapy

• Psilocybin and MDMA are available through Health Canada's Special Access Program (SAP) for individuals with serious conditions not responding to other treatments

• Section 56 exemptions have allowed some practitioners and patients to access psilocybin in specific contexts

• Integration therapy — therapeutic support around an experience, without being present during it — is fully legal regardless of the substance context

• The legal landscape continues to evolve; checking current Health Canada guidance and speaking with a knowledgeable provider is essential

Ketamine

Ketamine is currently the most legally accessible psychedelic-adjacent treatment in Canada. It's an approved anesthetic that can be prescribed off-label for treatment-resistant depression and other conditions. Ketamine clinics operate in major cities across Canada, offering intravenous infusions, intramuscular injections, and sometimes ketamine-assisted psychotherapy.

The evidence base for ketamine in treatment-resistant depression is solid. For PTSD and other trauma presentations, the evidence is growing. Ketamine-assisted therapy — where a therapist is present and engaged during the ketamine experience — is available at some clinics.

Psilocybin and MDMA via Special Access Program

Health Canada's Special Access Program (SAP) allows physicians to apply for access to restricted substances, including psilocybin and MDMA, for patients with serious conditions who have not responded to conventional treatments. This pathway exists but is not straightforward — it requires a physician application, meets specific criteria, and approval is not guaranteed.

Access through SAP has been used primarily for end-of-life distress and treatment-resistant PTSD in the context of MDMA research protocols. It is not a general access pathway.

Integration therapy as a legal and accessible option

For many people, the most immediately accessible option is psychedelic integration therapy — therapeutic support around an experience that occurred outside a clinical context. This is fully legal, doesn't require the therapist to be present during any experience, and can address experiences with psilocybin, MDMA, ayahuasca, cannabis, or other substances in non-clinical settings.

A therapist offering integration support is not facilitating drug use — they're providing psychological care for what arose during an experience the person had on their own terms.

Frequently asked questions

Can a therapist in Ontario provide integration therapy for psilocybin experiences?

Yes. A therapist in Ontario providing integration therapy — preparation and processing around an experience, without being present during it or providing the substance — is operating within the scope of regulated psychotherapy. The substance context of the experience doesn't change the legality of the therapeutic support.

Are there Indigenous or ceremonial contexts for accessing these medicines legally?

Traditional and ceremonial use of plant medicines exists in various Indigenous contexts in Canada. These fall under different legal and cultural frameworks than regulated health care. For non-Indigenous people seeking these pathways, there are ethical and legal complexities that deserve careful consideration — including the importance of not appropriating ceremonial contexts for therapeutic purposes.

Is the legal situation likely to change?

Yes, likely. The regulatory environment around psychedelic-assisted therapy has been shifting meaningfully in recent years. Staying current through Health Canada updates and providers working in this space is more reliable than any summary that may become outdated.